Valneva (VALN) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Product Sales: EUR 64 million, down from EUR 91 million in H1 2025, reflecting an 18.3% decrease at constant currency.

IXIARO Sales: EUR 44 million, decreased from EUR 54.7 million due to distributor transition and sales phasing.

DUKORAL Sales: EUR 14.7 million, down from EUR 17.4 million, impacted by prior year one-time sales and distributor transition.

IXCHIQ Sales: EUR 4.4 million, decreased from EUR 7.5 million, affected by previous year’s outbreak-related sales.

Total Revenues: EUR 65.8 million, down from EUR 97.6 million in H1 2025.

Operating Loss: EUR 49.9 million, compared to EUR 16.8 million in the prior year.

Adjusted EBITDA Loss: EUR 40.1 million, up from EUR 6 million in H1 2025.

Cash Position: EUR 121.5 million at June 30, 2026, an increase from EUR 109.6 million at the end of fiscal year 2025.

2Strategic Updates and Business Highlights

Lyme Disease Vaccine: Positive efficacy results (over 70%) reported, with Pfizer optimistic about regulatory decisions within the next 12 months. Valneva is the only late-stage Lyme vaccine candidate.

IXCHIQ: Focus shifting to endemic markets, with a pilot vaccination campaign in Brazil underway, vaccinating over 50,000 individuals.

Shigella Vaccine: In-licensed a tetravalent candidate, with two studies ongoing to assess immunogenicity and efficacy.

Restructuring Program: Implemented to enhance financial position, including workforce reduction and project reprioritization, expected to yield positive cash flow and P&L impact in H2 2026.

3Forward Guidance and Outlook

2026 Financial Guidance: Reaffirmed product sales of EUR 135 million to EUR 150 million and total revenues of EUR 145 million to EUR 160 million.

Operational Cash Flow: Expected to remain positive, with improvements in gross margins anticipated in H2 2026 following non-recurring effects in H1.

Long-term Strategy: Aiming for financial self-sustainability starting in 2027, contingent on the success of the Lyme vaccine.

4Bad News, Challenges, or Points of Concern

Declining Sales: Significant decreases in product sales across key products, particularly IXIARO and DUKORAL, due to distributor transitions and market conditions.

Operating Losses: Increased operating losses and adjusted EBITDA losses highlight ongoing financial pressures.

Regulatory Risks: Uncertainty around the regulatory approval process for the Lyme vaccine, with potential need for additional studies or data submissions.

Market Conditions: Weakening travel market affecting IXCHIQ sales and potential geopolitical factors impacting overall performance.

5Notable Q&A Insights

Regulatory Update: Pfizer is making progress with regulatory agencies, but specifics on timelines for U.S. vs. European submissions remain unclear.

Shigella Program Delays: Delays attributed to the acquisition of LimmaTech by Lilly, but data validation is nearing completion.

Strategic Focus: Emphasis on maximizing cash generation from the commercial business to reinvest in R&D, with Lyme vaccine success being pivotal for future investments.

Cost Management: Continued focus on reducing SG&A and R&D expenses, with expectations for improved gross margins in the second half of 2026. Overall, Valneva's Q2 2026 results reflect significant challenges in sales and profitability, but strategic initiatives and potential regulatory successes, particularly with the Lyme vaccine, provide a cautiously optimistic outlook for the company’s future.